Government officials in China have accused the former head of GlaxoSmithKline's (GSK) operations in China, British executive Mark Reilly, of bribing doctors and hospital officials to use GSK's products. The Ministry of Public Security in China has also alleged that Reilly, along with other GSK executives, had attempted to cover up a government investigation of the bribery accusation.
Faegre Baker Daniels partner Bing Wang, based in the firm's Beijing office, expressed his shock over the behavior of Reilly in the South China Morning Post. "British companies have strict ethical and anti-bribery rules. It is really mind-boggling how a British [executive] can behave like this. It is rare for a British [executive] to be involved in such a scheme in such a blatant manner," Wang said.
Amidst the bribery allegations, Reilly was replaced as GSK's China head in July 2013 and could face a prison term if convicted.